5 completed, 1 unknown. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Unknown 1 |
Follow Celon Pharma SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis CPL409116, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Celon Pharma SA | 106 | 2022-05-01 | 2025-01-23 |
| Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes CPL207280, Placebo - Type 2 Diabetes | Phase 2 | Unknown | Celon Pharma SA | 80 | 2022-01-21 | 2023-02-08 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia CPL500036 - low dose, CPL500036 - high dose, Placebo - Schizophrenia | Phase 2 | Completed | Celon Pharma SA | 189 | 2021-05-19 | 2025-09-10 |
| Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose - Bipolar Depression | Phase 2 | Completed | Celon Pharma SA | 88 | 2019-03-28 | 2021-03-19 |
| Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose - Major Depressive Disorder | Phase 2 | Completed | Celon Pharma SA | 88 | 2019-02-25 | 2020-04-28 |
Arthritis, Rheumatoid (1) · Bipolar Disorder (1) · Depressive Disorder, Major (1) · Diabetes Mellitus, Type 2 (1) · Dyskinesia, Drug-Induced (1) · Parkinson Disease (1) · Schizophrenia (1)
CPL207280 (1)
Poland (6) · Ukraine (3) · Hungary (1)